Interchangeability for Biologics is a Legal Distinction in the USA, Not a Clinical One

Biologics are increasingly vital medicines that significantly reduce morbidity as well as mortality, yet access continues to be an issue even in apparently wealthy countries, such as the USA. While patient access is expected to improve with the introduction of biosimilars, misperceptions in a signif...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Joseph P., Jung, Byoungin, Park, Hyung Ki, Shin, Donghoon, Jung, Jin Ah, Ghil, Jeehoon, Han, Jihyun, Kim, Kyung Ah, Woollett, Gillian R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Current Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9190447/
https://www.ncbi.nlm.nih.gov/pubmed/35696067
http://dx.doi.org/10.1007/s40259-022-00538-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9190447/
https://www.ncbi.nlm.nih.gov/pubmed/35696067
http://dx.doi.org/10.1007/s40259-022-00538-6

Ejemplares similares